9 mei 2012: al in 2005 werd een meta analyse van studies gedaan met Ukrain bij alvleesklierkanker gepubliceerd. Daarna kan ik geen gerandomiseerde studies meer vinden. Wel dierstudies en laboratorium studies. Overigens is de conclusie van de meta analyse kritisch over de betrouwbaarhied van de studie resultaten, al zeggen ze wel dat ze geen bewijs voor fraude hebben gevonden.

Als u hier klikt kunt u het volledige studieverslag uit 2006 gratis inzien. Onderaan staat het abstract van die studie. Als u hier klikt komt u op de website pagina over Ukrain van het Memorial Solan-Kettering Hospital in New York. Onderaan staat ook referentielijst van studies gedaan met Ukrain. Laatste studie uit die lijst is uit 2011. 

Kijk op deze website voor actuele informatie over het middel Ukrain.

Op deze website staat ook een en ander over Ukrain en zij presenteren zich als officiele grondleggers van Ukrain maar de website maakt een amateuristische indruk en of dit betrouwbaar is weet ik niet.

21 december 2004: Bron: Pubmed: Langenbecks Arch Surg. 2002 Mar;386(8):570-4. Epub 2002 Feb 13.

Fase II studie bewijst bij 90 patiënten dat Ukrain de overlevingstijd van niet operabele alvleesklierkankerpatiënten bijna verdubbeld. Of Ukrain nu alleen of in combinatie met gemzar werd gegeven maakte weinig verschil in uiteindelijke overlevingscijfers. Met Gemzar erbij was de overleving zelfs nog iets langer dan alleen met Ukrain.

NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.

Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, Cammerer G, Leder G, Beger HG. Department of General Surgery, University of Ulm, Germany.

BACKGROUND: NSC-631570 (Ukrain) is a semisynthetic compound of thiophosphoric acid and the alkaloid chelidonine from the plant Chelidonium majus. It has been used in complementary herbal medicine for more than 20 years for the treatment of benign and malignant tumors.

PATIENTS/METHODS: Between August 1999 and June 2001, 90 patients with histologically proven unresectable pancreatic cancer were randomized in a monocentric, controlled, randomized study. Patients in arm A received 1000 mg gemcitabine/m2, those in arm B received 20 mg NSC-631570, and those in arm C received 1000 mg gemcitabine/m2 followed by 20 mg NSC-631570 weekly. End point of the study was overall survival.

RESULTS: In all three arms therapy was well tolerated and toxicity was moderate. At the first re-evaluation in arm A 32%, in arm B 75%, and in arm C 82% showed no change or partial remission according to WHO criteria (arm A versus arm B: P<0.01, arm A versus arm C: P<0.001). Median survival according to Kaplan-Meier analysis was in arm A 5.2 months, in arm B 7.9 months, and in arm C 10.4 months (arm A versus arm B: P<0.01, arm A versus arm C: P<0.01). Actuarial survival rates after 6 months were 26%, 65% and 74% in arms A B and C, respectively (arm A versus arm B: P<0.05, arm A versus arm C P<0.01).

CONCLUSION: We could show that in unresectable advanced pancreatic cancer, NSC-631570 alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer.

Ukrain – a new cancer cure? A systematic review of randomised clinical trials

BMC Cancer. 2005 Jul 1;5:69.

Ukrain - a new cancer cure? A systematic review of randomised clinical trials.

Ernst E, Schmidt K.

Source

Complementary Medicine, Peninsula Medical School, Universities of Exeter & Plymouth, 25 Victoria Park Road, Exeter EX2 4NT. edzard.ernst@pms.ac.uk

Abstract

BACKGROUND:

Ukrain is an anticancer drug based on the extract of the plant Chelidonium majus L. Numerous pre-clinical and clinical investigations seem to suggest that Ukrain is pharmacologically active and clinically effective. We wanted therefore to critically evaluate the clinical trial data in the form of a systematic review.

METHODS:

Seven electronic databases were searched for all relevant randomised clinical trials. Data were extracted and validated by both authors, tabulated and summarised narratively. The methodological quality was assessed with the Jadad score.

RESULTS:

Seven trials met our inclusion criteria. Without exception, their findings suggest that Ukrain has curative effects on a range of cancers. However, the methodological quality of most studies was poor. In addition, the interpretation of several trials was impeded by other problems.

CONCLUSION:

The data from randomised clinical trials suggest Ukrain to have potential as an anticancer drug. However, numerous caveats prevent a positive conclusion, and independent rigorous studies are urgently needed.

PMID:
15992405
[PubMed - indexed for MEDLINE]

PMCID:
PMC1180428

References
  1. Uglyanitsa KN, et al. Ukrain: a novel antitumor drug. Drugs Exp Clin Res 2000;56:347-56.
  2. Colombo ML, Bosisio E. Pharmacological activities of Chelidonium majus L. (papaveracea). Pharmacol Res 1996;33:127-34.
  3. Panzer A, et al. Ukrain™, a semisynthetic chelidonium majus alkaloid derivative, acts by inhibition of tubulin polymerization in normal and malignant cell lines. Cancer Lett 2000;160:149-57.
  4. Danysz A, Kokoschinegg M, Hamler F. Clinical studies of Ukrain in health volunteers (phase I). Drugs Exp Clin Res 1992;18:39-43.
  5. Jagiello-Wojtowicz E, et al. Preliminary pharmacokinetic studies of Ukrain in rats. Drugs Exp Clin Res 1998;24:309-11.
  6. Gansauge F, et al. NSC-631570 24(Ukrain) in the palliative treatment of pancreatic cancer: results of a phase II trial. Langenbeck’s Arch Surg 2002;386:570-4.
  7. Ernst E, Schmidt K. Ukrain - a new cancer cure? A systematic review of randomized clinical trials. BMC Cancer 2005; 5(1):69.
  8. Gansauge F, Ramadani M, Schwarz M, et al. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterology. 2007 Apr-May;54(75):917-20.
  9. Skivka LM, Trompak OO, Kudryavets YI, Bezdenezhnykh NA, Susak YM. The effect of NSC-631570 (Ukrain) alone and in combination with pathogen-associated molecules on cell cycle distribution and apoptosis induction of mouse melanoma cells with different biological properties. Exp Oncol. 2010 Jul;32(2):92-6.
  10. Skivka L, Susak Y, Trompak O, et al. The effect of monotherapy and combined therapy with NSC-631570 (Ukrain) on growth of low- and high-metastasizing B16 melanoma in mice. J Oncol Pharm Pract. 2010 Sep 3. [Epub ahead of print]
  11. Venkatesh K, Govindaraj S, Ramachandran A, et al. Effect of Ukrain on Cell Survival and Apoptosis in the Androgen-Independent Prostate Cancer Cell Line PC-3. J Environ Pathol Toxicol Oncol. 2011;30(1):11-9.

alvleesklierkanker, gemzar


Plaats een reactie ...

Reageer op "Ukrain al of niet in combinatie met Gemzar - gemcitabine zorgt voor verdubbeling van overlevingstijd bij inoperabele alvleesklierkankerpatiënten, aldus gerandomiseerde fase II studie met 90 patiënten."


Gerelateerde artikelen
 

Gerelateerde artikelen

Divers Microbioom met vier >> Immunonutrition - immuunstimulerend >> Synbiotica pre operatief voorkomt >> Vitamine D - calcipotriol >> L-carnitine, een aminozuur, >> Triptolide, een werkzame stof >> Ukrain al of niet in combinatie >> Ukrain een natuurlijk product >> Voeding en voedingsstoffen: >>